- Raw materials
- Alkalinizing agents
- Dihydroxyaluminum sodium carbonate
Dihydroxyaluminum sodium carbonate API Manufacturers & Suppliers
0 verified results
All Dihydroxyaluminum sodium carbonate data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Dihydroxyaluminum sodium carbonate | CAS No: 16482-55-6 | GMP-certified suppliers
A medication that serves as an experimental aluminum-based compound potentially applicable in gastrointestinal conditions requiring acid neutralization or phosphate binding.
Therapeutic categories
Product Snapshot
- Dihydroxyaluminum sodium carbonate is an oral tablet formulation
- It is primarily used for gastrointestinal indications
- The product is currently in an experimental approval status and not approved by major regulatory agencies
Clinical Overview
The mechanism of action for dihydroxyaluminum sodium carbonate has not been explicitly characterized. As an aluminum-based compound, it is likely related chemically to other aluminum hydroxides that act as antacids or phosphate binders through neutralization of gastric acid or binding negatively charged molecules; however, specific pharmacological or clinical activity data are not documented.
Absorption, distribution, metabolism, and excretion (ADME) parameters for this compound remain unspecified. Typically, aluminum compounds exhibit minimal systemic absorption when administered orally, with the majority excreted via the feces. However, without direct data, the ADME characteristics of dihydroxyaluminum sodium carbonate cannot be conclusively described.
Safety and toxicity information for this compound is limited. Aluminum-containing agents have been associated with neurotoxicity and other adverse effects in cases of excessive exposure or impaired renal function. Because its clinical use is experimental and lacks established safety data, rigorous toxicological evaluation would be necessary before any therapeutic application.
No marketed pharmaceutical products containing dihydroxyaluminum sodium carbonate have been identified. Usage contexts are therefore primarily experimental or investigational.
From an API sourcing perspective, due diligence on supplier quality, chemical purity, and compliance with regulatory standards is essential due to the lack of established pharmaceutical use. Analytical verification of identity, impurity profiling, and batch-to-batch consistency should be prioritized to ensure suitability for research or development purposes.
Identification & chemistry
| Generic name | Dihydroxyaluminum sodium carbonate |
|---|---|
| Molecule type | Small molecule |
| CAS | 16482-55-6 |
| UNII | 84H8Z9550J |
| DrugBank ID | DB15825 |
Formulation & handling
- Dihydroxyaluminum sodium carbonate is formulated for oral administration in tablet form.
- As a small molecule with high water solubility, dissolution considerations are straightforward.
- Stability and handling focus on maintaining solid-state integrity without specialized conditions.
Regulatory status
Dihydroxyaluminum sodium carbonate is a type of Alkalinizing agents
Alkalinizing agents, a pharmaceutical API category, refers to a group of substances used to increase the pH (alkalinity) of a solution or body fluid. These agents play a crucial role in various medical applications, such as the treatment of acidosis, kidney disorders, and certain drug overdoses.
One commonly used alkalinizing agent is sodium bicarbonate, which is highly effective in raising the pH of blood and urine. It works by neutralizing excess acid and restoring the acid-base balance in the body. Sodium bicarbonate is often administered intravenously in emergency situations to rapidly correct severe acidosis.
Another alkalinizing agent, acetazolamide, is frequently employed in the treatment of glaucoma and certain types of epilepsy. By inhibiting carbonic anhydrase, acetazolamide reduces the production of bicarbonate ions, leading to a systemic decrease in pH. This mechanism is particularly useful in lowering the intraocular pressure associated with glaucoma.
Alkalinizing agents are also utilized in the management of certain drug toxicities. For instance, methotrexate, a chemotherapy medication, can cause severe toxicity if its elimination is hindered. Alkalinizing the urine with agents like sodium bicarbonate enhances methotrexate solubility, preventing the formation of toxic crystals in the kidneys.
In conclusion, alkalinizing agents are indispensable pharmaceutical APIs that help correct acid-base imbalances, treat specific medical conditions, and mitigate drug toxicities. Their diverse applications make them valuable tools in modern medicine.
